Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Eligible for screening study DCP 001
EA9161 is approaching accrual goal. Therefore, EFFECTIVE April 23, 2021, protocol will be closed to new accrual.
EA9161 Quality of Life (QOL) component has reach accrual goal. Therefore, EFFECTIVE August 5, 2020, the QOL component is closed to new accrual.